viewPreveCeutical Medical Inc.

Prevecuetical Medical to develop treatment for anxiety

Anxiety disorders refer to a group of mental disorders characterized by feelings of anxiety and fear, including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder and posttraumatic stress disorder.

Anxiety attack
Symptoms typically experienced by those with anxiety disorders can make it a chronic disorder rather than an episodic disorder.

PreveCeutical Medical Inc (CNSX:PREV) said the first product of its newly-created medicinal cannabis division will be for the treatment of anxiety.

The company said the goal of its medicinal cannabis division's product development program is to create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.

READ PreveCeutical Medical shares head north as it launches medical cannabis division​

The Anxiety Disorders Association of Canada claims that one in four Canadians will suffer from an anxiety disorder at some point in their life.

Common treatments are not always effective and are known to have side effects, including insomnia, agitation and sexual dysfunction.  

Quick facts: PreveCeutical Medical Inc.

Price: 0.045 CAD

Market: CSE
Market Cap: $22.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read